Results 231 to 240 of about 50,964 (281)
Some of the next articles are maybe not open access.
Steroidogenesis in castration-resistant prostate cancer
Urologic Oncology: Seminars and Original Investigations, 2023Castration resistance is in part attributable to aberrant activation of androgen receptor (AR) signaling by the intracrine activation of androgen precursors derived from adrenal glands. To overcome this, novel AR pathway inhibitors (ARPIs) that suppress androgen synthesis by CYP17 inhibition or AR activation by antiandrogen effects have been developed.
Masaki Shiota +4 more
openaire +2 more sources
Overcoming castration resistance in prostate cancer
Current Opinion in Urology, 2012Recent advances in our understanding of the androgen axis signaling pathway have led to the development of therapeutic strategies to overcome the state of 'castration resistance' in prostate cancer. In this review, we examine the mechanisms of castration resistance, as well as recently reported and ongoing clinical studies, which will further identify ...
Che-Kai, Tsao +3 more
openaire +2 more sources
The hallmarks of castration-resistant prostate cancers
Cancer Treatment Reviews, 2015Prostate cancer has become a real public health issue in industrialized countries, mainly due to patients' relapse by castration-refractory disease after androgen ablation. Castration-resistant prostate cancer is an incurable and highly aggressive terminal stage of prostate cancer, seriously jeopardizing the patient's quality of life and lifespan.
Maria, Katsogiannou +5 more
openaire +2 more sources
Immunotherapy for Castration-Resistant Prostate Cancer
Urologic Clinics of North America, 2012The improved survival with sipuleucel-T, an autologous antigen-presenting cell-based agent, for the treatment of patients with metastatic asymptomatic and minimally symptomatic castration-resistant prostate cancer supports immunotherapy as a valid approach. Also, multiple novel immunotherapeutic approaches are undergoing vigorous investigation.
Guru, Sonpavde, Philip W, Kantoff
openaire +2 more sources
Castration-Resistant Prostate Cancer
Urologic Clinics of North America, 2017Men with advanced prostate cancer are typically treated with hormonal therapy, which results in tumor shrinkage. However, tumors relapse and develop into a highly aggressive and lethal form of the disease, termed castration-resistant prostate cancer (CRPC).
Kelly Stratton, Michael Cookson
openaire +2 more sources
New developments in castrate‐resistant prostate cancer
BJU International, 2012Castrate‐resistant prostate cancer (CRPC) occurs when disease progresses in the presence of castrate levels of androgens and remains sensitive to further hormonal manipulation. For many years the treatment of CRPC was limited to the use of docetaxel for metastatic disease.
Shore, N., Mason, M., de Reijke, Th M.
openaire +2 more sources
Emerging therapies in castrate-resistant prostate cancer
Current Opinion in Oncology, 2009Prostate cancer continues to represent a major health problem. It represents the most common cancer in US men, with an estimated 186 320 new cases diagnosed in 2008. It is the second leading cause of cancer death in men in the United States. Despite several attempts, the median survival for men with metastatic castrate-resistant prostate cancer is 1-2 ...
Kiran, Lassi, Nancy A, Dawson
openaire +2 more sources
The Molecular Evolution of Castration-resistant Prostate Cancer
European Urology Focus, 2016Androgen deprivation therapy (ADT) is the backbone of treatment for advanced prostate cancer. However, castration-resistant prostate cancer (CRPC) nearly invariably develops through a range of different molecular mechanisms accompanied by progression to a more aggressive phenotype.To understand the key molecular mechanisms leading to CRPC and the ...
Yvonne, Ceder +5 more
openaire +2 more sources